EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis

Terhi T Piltonen, Johanna Viita-Aho, Ulla Saarela, Johanna Melin, Maria Forslund

Seminars in Reproductive Medicine · 01.03.2024 · 42 (01) · 049-059

DOI: 10.1055/s-0044-1786731 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Reproductive Medicine, erschienen am 01.03.2024. Verfasst von Terhi T Piltonen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, Medical Research Center Oulu, University of Oulu, Oulu University Hospit…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Anti-Mullerian Hormone. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2023 international evidence-based guideline update for the assessment and management of polycystic ovary syndrome (PCOS) recommends using the Rotterdam criteria for the diagnosis of PCOS. The updated guideline has evidence-based recommendation for the diagnosis, and it now also includes serum anti-Müllerian hormone (AMH) measurement as an alternative tool for gynecological ultrasound to diagnose polycystic ovary morphology (PCOM). The aim of this new recommendation was to facilitate PCOS diagnostic workup in primary care and other disciplines, as currently most diagnosing is done in gynecology and infertility clinics. Here, we review factors affecting AMH levels as well as the utility of AMH in PCOS diagnosis. We identified relevant studies that report different cut-offs for AMH to diagnose PCOM as part of PCOS diagnosis. There are, however, some limitations when using AMH that should be acknowledged. These include physiological aspects like age, ethnicity, and obesity and iatrogenic causes like hormonal medication and ovarian surgery. Also reference ranges are different depending on AMH assay used. As a summary, we conclude that AMH is a usable tool in PCOM diagnostics, but it does not have a single cut-off. Therefore, further studies are needed to establish age and assay-based reference ranges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeAnti-Mullerian HormoneHumansFemaleBiomarkers

Substanzen

Anti-Mullerian HormoneBiomarkers

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, Medical Research Center Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland.
  • Department of Obstetrics and Gynecology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
  • Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Förderung

  • Academy of Finland

Zitieren

APA

Piltonen, T. T., Viita-Aho, J., Saarela, U., Melin, J., & Forslund, M. (2024). Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis. Seminars in Reproductive Medicine, 42(01), 049-059. https://doi.org/10.1055/s-0044-1786731

Vancouver

Piltonen TT, Viita-Aho J, Saarela U, Melin J, Forslund M. Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis. Seminars in Reproductive Medicine. 2024;42(01):049-059. doi:10.1055/s-0044-1786731

BibTeX
@article{Piltonen2024,
  author = {Piltonen, Terhi T and Viita-Aho, Johanna and Saarela, Ulla and Melin, Johanna and Forslund, Maria},
  title = {Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis},
  journal = {Seminars in Reproductive Medicine},
  year = {2024},
  volume = {42},
  number = {01},
  pages = {049--059},
  doi = {10.1055/s-0044-1786731}
}
Kostenlos starten →